- Matica Biotechnology has entered into a CDMO agreement with VaxDome to provide process development, analytical development, and production of non-GMP and cGMP clinical materials for VaxDome’s hybrid antiviral vaccine candidates.
- The work will be conducted at Matica Bio’s facility in College Station, Texas, supporting the program from early development through clinical manufacturing.
Matica Biotechnology has partnered with Texas-based biotechnology company VaxDome to support the development and clinical manufacturing of VaxDome’s antigen-agnostic antiviral-vaccine hybrid candidates. Under the agreement, the viral vector CDMO will provide process development, analytical development, and the manufacture of both non-GMP and cGMP clinical materials at its facility in College Station, Texas.
The collaboration supports VaxDome’s platform, which is designed to convert a selected influenza virus strain into an intranasally delivered antiviral-vaccine hybrid intended to provide broad protection against known and unknown viruses, as well as lung cancer. Matica Bio said it will manage development activities through clinical production, including the technical transition between manufacturing phases.
According to the companies, Matica Bio will leverage its expertise across viral and cell modalities, including adeno-associated virus (AAV), lentivirus, and oncolytic viruses, together with single-use technologies and inline process monitoring to support the program. The integrated contract manufacturing services are intended to enable process development, analytical testing, and GMP production within a single facility.
“VaxDome’s hybrid technology is a really fresh take on how we can treat and prevent viral infections in a wide variety of disease settings including flu.”
Paul Kim, CEO of Matica Bio
Matica Bio said it will oversee the technical transition throughout development to help ensure the final vaccine candidate meets applicable safety, purity, and regulatory requirements before entering clinical trials.
